MorphoSys Takes $252.1m Impairment Charge As It Slims Down R&D
The company will close down early-stage research programs brought under its wing through last year’s acquisition of Constellation Pharmaceuticals.
The company will close down early-stage research programs brought under its wing through last year’s acquisition of Constellation Pharmaceuticals.